Filtry
One year experience with Macugen in treatment of wet form of AMD
It was presented one year effectiveness and safety of Macugen therapy.
FF - ORL, oftalmologie, stomatologie
- 2008 •
- O
Rok uplatnění
O - Ostatní výsledky
Macugen in treatment of wet form of AMD, first experience
This work assesses the results of applying the first selective antagonist of VEGF Macugen (pegaptanib) for subfoveal choroidal neovascular membrane (CNV) in age-related macular degeneration (ARMD). Macugen is a modified oligonucleot...
FF - ORL, oftalmologie, stomatologie
- 2007 •
- O
Rok uplatnění
O - Ostatní výsledky
Macugen in treatment of age related macular degeneration
Author present results of therapy of wet form of age related macular degeneration by using of pegaptanib.
FF - ORL, oftalmologie, stomatologie
- 2009 •
- O
Rok uplatnění
O - Ostatní výsledky
Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year results
Pegaptanib (Macugen) is available in the Czech Republic for the treatment of neovascular age-related macular degeneration since April 2007. Pegaptanib is a de facto representative of the first agents that interact with anti-vascular growth f...
FF - ORL, oftalmologie, stomatologie
- 2009 •
- O
Rok uplatnění
O - Ostatní výsledky
First experience with Macugen therapy in wet AMD
Macugen (pegaptanib) is a modified oligonucleotide that specifically binds to the extracellular VEGF165, and inactivates it. Inhibits the processes of formation and progression of subretinal neovascularization. Selective inhibition of VEGF16...
FF - ORL, oftalmologie, stomatologie
- 2007 •
- O
Rok uplatnění
O - Ostatní výsledky
Pegaptanib (Macugen) 1.5 year results of treatment of wet AMD
The authors evaluated results achieved with the use of pegaptanib (Macugen) for wet age-related macular degeneration (AMD). Pegaptanib (Macugen, Pfizer) is the first antagonist of the vascular growth factor (VEGF), approved for intr...
FF - ORL, oftalmologie, stomatologie
- 2009 •
- O
Rok uplatnění
O - Ostatní výsledky
Pegaptanib (Macugen) in treatment of wet form of age related macular degeneration, 1.5 year experience
Authors in their work assess the results achieved by the use of pegaptanib (Macugen, a) for treatment of wet age-related macular degeneration (AMD). Pegaptanib (Macugen, Pfizer) is the first antagonist of the vascular growth factor ...
FF - ORL, oftalmologie, stomatologie
- 2009 •
- D
Rok uplatnění
D - Stať ve sborníku
Macugen in treatment of age related macular degeneration
The authors evaluated results achieved with the use of pegaptanib (Macugen) for wet age-related macular degeneration (AMD). Patients included in the sample were treated with repeated intraocular pegaptanib applications at an interval of 6 we...
FF - ORL, oftalmologie, stomatologie
- 2010 •
- O
Rok uplatnění
O - Ostatní výsledky
Results of the intravitreal anti-VEGF in the therapy of ROP
Anti-VEGF therapy has been used in the treatment of ROP at our clinic since 2009. Macugen and Abastin are used.
FF - ORL, oftalmologie, stomatologie
- 2015 •
- O
Rok uplatnění
O - Ostatní výsledky
Combined treatment in treatment of retinalangiomatous proliferation (Macugen and PDT with Visudyne)
The main task of this study was to evaluate the effectiveness of combination therapy (Macugen + PDT with Visudyne) in the treatment of retinal angiomatous proliferation. Conventionally used in monotherapy (PDT with Visudyne, or anti-VEGF) ha...
FF - ORL, oftalmologie, stomatologie
- 2009 •
- D
Rok uplatnění
D - Stať ve sborníku
- 1 - 10 z 15